Advancing precision immune medicine
Seconds from raw cytometry data to clinical decisions
When hema.to is right for you
Compared to conventional workflows, hema.to is...
Reproducible
Ensuring reproducible results is a cornerstone of our approach to cytometry analysis. Through rigorous data-driven analysis pipelines, we minimize variability and maximize consistency. This commitment to reproducibility ensures that results are reliable and support robust scientific conclusions within your laboratory.
Equally reliable
Our methods are equally reliable when compared with conventional cytometry analysis techniques. Our automated processes deliver results that are as dependable as traditional methods, giving you peace of mind that the integrity of your data is preserved and that the highest standards of data reporting are being maintained.
2.2x faster
Our platform accelerates the time from raw data to analysis results and reports by a factor of 2.2, significantly enhancing lab efficiency. This rapid turnaround time allows clinicians to make faster decisions and progress their workflow without sacrificing the accuracy or reliability of the data.
Lab customisable
Flexibility and customization are key features of our platform. Labs can utilize any standard operating procedure (SOP) and panel configuration they desire, and our system can be trained on their specific data. This adaptability ensures that the analysis is tailored to the unique requirements of each lab, optimizing performance and relevance of the results.
hema.to in figures
Products
Products
Achievements
We closed our €3.7M round, led by Elaia Partners
In 2022, we closed our seed round with Elaia Partners, heal capital and HTGF to bring precision diagnostics to immune medicine. Anne-Sophie Carrese says, about the deal: "We have been convinced by the founding team, composed of three former entrepreneurs from the same company, with three PhD profiles, at a stage where they are going to scale their go to market, which is coherent with our deep tech seed investment thesis", Managing Partner at Elaia Partners. See tech.eu's press release here.
hema.to won the 1st prize
In 2022, we've placed 1st at the Medical Valley Innovation Night, where we pitched hema.to to an excellent jury consisting of members of Medical Valley EMN e. V., Siemens Healthineers, aescuvest, GWQ ServicePlus AG, IONOS and Fraunhofer IIS.
hema.to placed 1st
In 2021, right after founding hema.to, it has been awarded the 1st place during the fantastic Start and Spread pitch competition which was organized by Manage and More by UnternehmerTUM.
I am very excited about implementing the decision support system developed by hema.to into the clinical flow cytometry lab space! It will help streamline and automate analyses workflows leading to improved accuracy and turn-around-times.
In the long run, there will be only three specialized hematology labs in the Netherlands — I think that hema.to will help us to be amongst them.
I really believe in what hema.to is doing. AI truly has the potential to help with many of our challenges in clinical flow cytometry including training new staff, not missing small pathologies or double pathologies, and taking better advantage of the large data sets we produce on any given sample for new diagnostic or predictive information.
The unique A.I.-based approach developed by hema.to has a transformative potential in cytometry, filling a high unmet need for this method that provides key health and biological metrics in many indications. We are proud and thrilled to join’s team in this endeavor.
for Strategic Initiatives and Director of Cellectis
Demonstrated quality
IVDD compliant
We are compliant with the In Vitro Diagnostic Directive (IVDD), meaning that we conform to ISO 13485 (quality management), ISO 14971 (risk management), ISO 62366 (usability), ISO 62304 (software life-cycle management) and IEC 82304 (health software).
Clinically proven
We have demonstrated expert-level performance at making differential diagnoses between the most common B-NHL types and healthy patients in two clinical studies. We've shown a mean accuracy of >99% on about 70% of cases and even the possibility to improve sensitivity and specificity as compared to conventional workflows (see publications).
GDPR compliant
Our application performs client-side anonymization, which means that your patient's name never even reaches our servers.
Scientifically backed
In a series of papers (Cell Patterns, Cytometry A, ASH blood I, ASH blood II), we have demonstrated that our core AI algorithms are capable of hematologist-level B-NHL classifications, and that this knowledge can be transfered across different flow protocols.